Zack Struver's blog
11 Groups Urge NIH to Lower Price of Xtandi, NIH/Army-Funded Prostate Cancer Drug With $129k/Year Price TagSubmitted by Zack Struver on 21. March 2016 - 12:34
+1 (914) 582-1428
FOR RELEASE: MARCH 21, 2016
Non-Profit Groups Urge Obama Administration, NIH to Lower Price of Government-Funded, $129,000 Per Year Prostate Cancer Drug
The groups asked the National Institutes of Health to “take this opportunity to act” to lower the price of the prostate cancer drug Xtandi and show leadership on deterring discriminatory pricing practices.
On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.
Submission of Knowledge Ecology International
U.S. Copyright Office Docket No. 2015-6
This is the submission of Knowledge Ecology International (KEI) in response to the U.S. Copyright Office request for public comment on “software-enabled consumer products” (U.S. Copyright Office Docket No. 2015-6).
Knowledge Ecology International is a non-governmental organization with offices in Washington, DC, and Geneva, Switzerland, that searches for better outcomes, including new solutions, to the management of knowledge resources.
This submission covers these topics:
On February 8, 2016, the National Institutes of Health (NIH) responded to Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment’s (UACT) letter requesting that the federal government exercise its authority under the Bayh-Dole Act to break patents on an expensive prostate cancer drug.
World Health Organization (WHO) Director-General Dr. Margaret Chan addressed civil society and policy-oriented “think tanks” on November 12, 2015, and “challenge[d]” them to “help with issues that keep me awake at night.” Specifically, she mentioned the problems with pharmaceutical patents, high drug prices as a barrier to access, and the current system of incentives for new drug innovation. Dr. Chan also raised concerns about the the TPP, which she said may raise drug prices and harm access to generics.
For Immediate Release
3 November 2015
Contact: Zack Struver, +1 (202) 332-2670 or firstname.lastname@example.org
Geneva — The World Trade Organization is poised to announce this Friday its approval of a limited 17-year extension of a 2001 waiver of obligations in the TRIPS Agreement, set to expire at the end of this year, the terms of which exempt Least Developed Countries (LDCs) from requirements to grant patents or related intellectual property rights on pharmaceutical products.
On October 23, 2015, the Harvard T.H. Chan School of Public Health hosted a forum titled "Drug Pricing: Public Health Implications," that was moderated by Caroline Humer, a Reuters healthcare correspondent. The forum featured a panel of four individuals who work on drug pricing:
- Steven Pearson, President of the Institute for Clinical and Economic Review and Lecturer at Harvard Medical School
On Wednesday, October 14, 2015, KEI staff and members of Public Citizen's Global Access to Medicines team demonstrated outside of the White House and USTR, urging the administration, especially USTR and Ambassador Michael Froman, to support a request for a permanent drug patent waiver for Least Developed Countries (LDCs) at the WTO.
Below are images from the protest action, also available in higher resolution here. And, yes, you can use these photos under any creative commons or wikimedia license.
Senator Bernie Sanders Asks USTR to Endorse Waiver of WTO Patent Rules for Least Developed CountriesSubmitted by Zack Struver on 28. September 2015 - 12:36
Knowledge Ecology International Press Release
28 September 2015
FOR IMMEDIATE RELEASE
CONTACT: Zack Struver
+1 (202) 332-2670
Senator Bernie Sanders asks USTR to endorse “indefinite waiver” of WTO requirements to grant drug patents for Least Developed Countries (LDCs)
KEI urges investigation of trade pressures on Least Developed Countries (LDCs) in light of Executive Order 13155Submitted by Zack Struver on 22. September 2015 - 7:43
Knowledge Ecology International sent letters today (attached to this release), September 21, 2015, to the Office of the General Counsel to the United States Trade Representative (USTR) and the Office of the Inspector General for the Department of Commerce, asking that they investigate USTR and the United States Patent and Trademark Office (USPTO) for the potential violation of an Executive Order issued by Bill Clinton — which prohibits the use of trade pressures to hinder polices related to access to HIV/AIDS medicines in sub-Saharan Africa — in their attempt to stop a request by Least Develop
This press release was distributed this morning, August 5, 2015, after KEI released the final sections of the TPP Chapter on Intellectual Property. The full text of the chapter is available here: http://keionline.org/tpp/11may2015-ip-text.
5 August 2015
CONTACT: Zack Struver
+1 (202) 332-2670
Knowledge Ecology International Leaks Copyright Provisions in Trans-Pacific Partnership